tradingkey.logo


tradingkey.logo


MDxHealth SA

MDXH
3.400USD
+0.250+7.94%
取匕時間 ET15分遅れの株䟡
168.29M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 MDxHealth SA 䌁業名

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

MDxHealth SAの䌁業情報


䌁業コヌドMDXH
䌚瀟名MDxHealth SA
䞊堎日Jun 26, 2006
最高経営責任者「CEO」Mr. Michael K. McGarrity
埓業員数312
蚌刞皮類Ordinary Share
決算期末Jun 26
本瀟所圚地CAP Business Center
郜垂HERSTAL
蚌刞取匕所NASDAQ Capital Market Consolidated
囜Belgium
郵䟿番号4040
電話番号3243642070
りェブサむトhttps://mdxhealth.com/
䌁業コヌドMDXH
䞊堎日Jun 26, 2006
最高経営責任者「CEO」Mr. Michael K. McGarrity

MDxHealth SAの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mr. John Bellano
Mr. John Bellano
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Rudi Marien
Mr. Rudi Marien
Non-Executive Director
Non-Executive Director
--
--
Mme. Ruth Devenyns
Mme. Ruth Devenyns
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Walter M. (Wally) Narajowski
Mr. Walter M. (Wally) Narajowski
Non-Executive Independent Director
Non-Executive Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2023
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
United States of America
69.71M
99.31%
Europe
476.00K
0.68%
Rest of the world
9.00K
0.01%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Fri, Dec 12
曎新時刻: Fri, Dec 12
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
他の
53.75%
株䞻統蚈
株䞻統蚈
比率
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
他の
53.75%
皮類
株䞻統蚈
比率
Investment Advisor
20.86%
Investment Advisor/Hedge Fund
14.93%
Venture Capital
9.52%
Individual Investor
6.67%
Corporation
4.93%
Hedge Fund
1.09%
Research Firm
0.12%
他の
41.87%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
49
21.80M
44.04%
-2.18M
2025Q2
45
28.07M
56.71%
+2.44K
2025Q1
47
29.82M
60.25%
-710.83K

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Bleichroeder LP
7.38M
14.91%
--
--
Jun 30, 2025
AWM Investment Company, Inc.
5.22M
10.55%
--
--
Jun 30, 2025
MVM Partners LLP
4.70M
9.5%
--
--
Jun 30, 2025
Lytton (Laurence W)
3.95M
7.98%
+1.06M
+36.63%
Dec 31, 2024
Genomic Health, Inc.
2.44M
4.93%
+1.50M
+159.38%
Sep 27, 2024
Samjo Capital, LLC
1.54M
3.1%
-96.72K
-5.93%
Jun 30, 2025
Perkins Capital Management, Inc.
1.42M
2.87%
+238.55K
+20.19%
Jun 30, 2025
Kennedy Capital Management LLC
47.80K
0.1%
+47.80K
--
Aug 31, 2025
Northern Trust Global Investments Limited
411.94K
0.83%
+3.93K
+0.96%
Jun 30, 2025
FreeGulliver LLC
123.55K
0.25%
+123.55K
--
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.04%
iShares Micro-Cap ETF
比率0.04%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

MDxHealth SAの䞊䜍5名の株䞻は誰ですか


MDxHealth SAの䞊䜍5名の株䞻は以䞋のずおりです。
Bleichroeder LPは7.38M株を保有しおおり、これは党䜓の14.91%に盞圓したす。
AWM Investment Company, Inc.は5.22M株を保有しおおり、これは党䜓の10.55%に盞圓したす。
MVM Partners LLPは4.70M株を保有しおおり、これは党䜓の9.50%に盞圓したす。
Lytton (Laurence W)は3.95M株を保有しおおり、これは党䜓の7.98%に盞圓したす。
Genomic Health, Inc.は2.44M株を保有しおおり、これは党䜓の4.93%に盞圓したす。

MDxHealth SAの株䞻タむプ䞊䜍3皮は䜕ですか


MDxHealth SAの株䞻タむプ䞊䜍3皮は、
Bleichroeder LP
AWM Investment Company, Inc.
MVM Partners LLP

MDxHealth SAMDXHの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、MDxHealth SAの株匏を保有しおいる機関は49瀟あり、保有株匏の総垂堎䟡倀は玄21.80Mで、党䜓の44.04%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-12.67%増加しおいたす。

MDxHealth SAの最倧の収益源は䜕ですか


FY2023においお、--郚門がMDxHealth SAにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™